What's Happening?
Scientists have discovered six new genetic links associated with hyperemesis gravidarum (HG), a severe form of morning sickness affecting about two percent of pregnant women. This study, the largest of its kind, was conducted by the Keck School of Medicine
of the University of South Carolina and international collaborators, analyzing genetic data from nearly half a million women. The research confirmed the gene GDF15 as a significant factor in HG and identified nine additional genes, six of which are newly associated with the condition. These findings suggest that genetic variants affecting hormone sensitivity, particularly GDF15, play a crucial role in the severity of nausea during pregnancy. The study also highlights the potential for new treatment pathways, including the use of metformin, a diabetes medication, to manage HG symptoms.
Why It's Important?
The identification of these genetic links is significant as it opens new avenues for understanding and treating hyperemesis gravidarum, a condition that can lead to severe dehydration, malnourishment, and hospitalization for pregnant women. Current treatments are limited, with medications like Zofran only partially effective for some patients. The genetic discoveries could lead to more personalized treatment options, potentially improving outcomes for affected women. Additionally, understanding the genetic basis of HG may help in developing preventive strategies, reducing the risk of complications for both mothers and their babies.
What's Next?
The research team has received approval to conduct a clinical trial testing the efficacy of metformin in reducing HG symptoms. This trial will explore whether pre-pregnancy administration of metformin can decrease sensitivity to GDF15 and lower the risk or severity of HG in women with a history of the condition. If successful, this could lead to new guidelines for managing HG, offering relief to many women who suffer from this debilitating condition.
